Those who work with Pro Medicus $PME (-2,12 %) yet, you should definitely do so! The Australian software company offers innovative solutions for medical imaging and data management and convinces with a highly profitable Software-as-a-Service (SaaS) model.
🔍 The business model at a glance:
✅ Visage imaging platform
- Core solution: "Visage 7", a cloud-based PACS software for managing and analyzing medical images (CT, MRI, X-ray).
- Pay-per-use modelRevenue is generated per examined image or scan.
✅ Long-term SaaS contracts
- Cooperation with leading clinics, especially in the USA.
- Contracts with terms of 5-7 years provide for stable, recurring sales.
✅ Cloud-first approach
- Hosting via Google Cloud or AWSwhich means customers do not need their own servers.
- Scalable and cost-efficient.
✅ High margins & premium customers
- Gross margin of 70-77 % thanks to low variable costs.
- Focus on high-priced radiology centers & university hospitals.
✅ Growth through expansion & innovation
- Expansion in the USA & Europe, increased use of AI-supported diagnostic tools.
📊 Fundamental key figures (10-year growth per year):
📈 Turnover: +28,11 %
💰 Dividend: +37,02 %
💵 Cash flow: +40,14 %
💸 Profit: +43,18 %
🏦 Financial strength & dividend outlook
- Debt is fully covered by core assets and could be repaid in around one year.
- High cash position enables investments in future technologies or the repurchase of further share packages
- Current dividend yield: 0.16but strong growth potential - analysts forecast a personal dividend yield of personal dividend yield of 7.75 % by 2040.
⚡ Conclusion:
Pro Medicus $PME (-2,12 %) stands for growth, innovation and financial strength. The company has established itself as a leading provider in the field of medical imaging & AI-supported diagnostics and and convinces through a scalable, highly profitable business model with with recurring revenues.
Disclaimer:
This analysis is for for information purposes only and does not constitute does not constitute investment advice or a recommendation to buy/sell for financial instruments. It is not an invitation to trade in securities. Historical performance is not an not an indicator of future results. Investments in securities involve risks and should be carefully considered.